Biodexa Pharmaceuticals Plc ADR (BDRX) concluded trading on Wednesday at a closing price of $1.03, with 54.7 million shares of worth about $56.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -75.48% during that period and on June 18, 2025 the price saw a gain of about 29.35%. Currently the company’s common shares owned by public are about 0.67M shares.
Stock saw a price change of -8.85% in past 5 days and over the past one month there was a price change of -20.16%. Year-to-date (YTD), BDRX shares are showing a performance of -74.57% which decreased to -95.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.78 but also hit the highest price of $41.50 during that period. The average intraday trading volume for Biodexa Pharmaceuticals Plc ADR shares is 2.19 million. The stock is currently trading -8.06% below its 20-day simple moving average (SMA20), while that difference is down -21.02% for SMA50 and it goes to -74.63% lower than SMA200.
Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX) currently have 0.67M outstanding shares and institutions hold larger chunk of about 25.04% of that.
The stock has a current market capitalization of $0.69M and its 3Y-monthly beta is at 1.20. It has posted earnings per share of -$17.42 in the same period. It has Quick Ratio of 1.75 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BDRX, volatility over the week remained 21.45% while standing at 10.01% over the month.
Stock’s fiscal year EPS is expected to rise by 59.49% while it is estimated to increase by 75.05% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on February 08, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it.
